Subgroup | Number of study | OR | 95% CI | Q | I2 | P-value |
---|---|---|---|---|---|---|
Overall | 18 | 4.67 | 2.65 to 8.21 | 73.99 | 77.00% | Â |
Age ≤ 65 | 9 | 5.03 | 2.53 to 10.0 | 27.96 | 71.40% |  |
Age > 65 | 3 | 0.91 | 0.57 to 1.41 | 2.21 | 9.400% | < 0.0001 |
Stage I > 49.5% | 5 | 4.11 | 1.90 to 8.91 | 12.76 | 68.60% |  |
Stage I ≤ 49.5% | 4 | 2.81 | 0.87 to 9.09 | 19.42 | 84.60% | 0.5944 |
M2F ≤ 69% | 6 | 5.98 | 2.04 to 17.53 | 16.66 | 70.00% |  |
M2F > 69% | 6 | 2.13 | 0.99 to 4.55 | 29.05 | 82.80% | 0.1246 |
MSP | 8 | 5.16 | 2.01 to 13.26 | 44.61 | 84.30% | Â |
qMSP | 10 | 4.32 | 2.08 to 8.94 | 29.28 | 69.30% | 0.7685 |
Diagnose | 13 | 6.79 | 2.99 to 15.44 | 59.54 | 79.80% | Â |
Non-diagnose | 5 | 2.59 | 1.33 to 5.05 | 11.56 | 65.40% | 0.0745 |
Multiple targets | 15 | 4.08 | 2.28 to 7.34 | 62.99 | 77.80% | Â |
Single target | 3 | 18.72 | 1.23 to 283 | 9.03 | 77.80% | 0.2836 |
Heterogeneous | 12 | 8.33 | 3.77 to 18.39 | 35.71 | 69.20% | Â |
Autogenous | 6 | 2.25 | 1.06 to 4.77 | 27.19 | 81.60% | 0.0187 |
Serum | 5 | 11.54 | 2.87 to 46.40 | 10.4 | 61.50% | Â |
Tissue | 13 | 3.72 | 2.03 to 6.78 | 55.18 | 78.30% | 0.14 |
Ad2Sc < 2 | 9 | 2.46 | 1.35 to 4.48 | 35.79 | 77.00% |  |
Ad2Sc > = 2 | 2 | 17.1 | 4.68 to 62.7 | 0.11 | 0.000% | 0.0077 |
Primer set I | 5 | 5.41 | 2.43 to 12.04 | 13.71 | 70.80% | Â |
Primer set II | 4 | 1.82 | 1.05 to 3.13 | 4.57 | 34.30% | 0.0137 a |